Raptor Pharmaceutical Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-12-26: Form 8-K; Period of report 2012-12-26; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events; Details 1.01.
- 2012-12-07: Form 8-K; Period of report 2012-12-07; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
- 2012-11-15: Form 8-K; Period of report 2012-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-11-06: Form 8-K; Period of report 2012-11-05; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-12-26 | 8-K | 2012-12-26 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth above in Item 1.01 of this Current Report on Form 8-K that relates to the creation of a direct financial obligation of the Company is incorporated by reference herein. 8.01 On December 20, 2012, the Company issued a press release titled "Raptor Pharmaceutical Corp. Signs $50 Million Loan Agreement With HealthCare Royalty Partners." The December 20, 2012 press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. | raptor8k_122612.htm |
| 2012-12-07 | 8-K | 2012-12-07 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 (b) On December 4, 2012, the Board of Directors of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), approved a change in the Company's fiscal year end from August 31 to December 31. | raptor8k_120712.htm |
| 2012-11-15 | 8-K | 2012-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release reporting its financial results for its fourth quarter and fiscal year ended August 31, 2012. | raptor8k_111412pr.htm |
| 2012-11-06 | 8-K | 2012-11-05 | 8.01 Other Events | 8.01 On November 5, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A. Abt, M.D., Professor of Kidney Diseases and Tenured Professor of Pediatrics, Northwestern University Feinberg School of Medicine, presented on Saturday, November 3rd a "Late Breaking" poster entitled "Extended Treatment with RP 103 in Patients with Nephropathic Cystinosis" at Kidney Week 2012, presenting data from the Company's RP103 (cysteamine bitartrate delayed-release) extension study. | raptor8k_110612.htm |
| 2012-11-02 | 8-K | 2012-11-01 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On November 1, 2012, Raptor Pharmaceutical Corp. (the "Company") issued a press release to report financial highlights for its fiscal year ended August 31, 2012. 8.01 In the November 1, 2012 press release, the Company also provided an update with respect to its clinical programs, including the ongoing extension study of PROCYSBI™ (cysteamine bitartrate) delayed-release capsules for the potential treatment of patients with nephropathic cystinosis and studies on the use of RP103 for the potential treatment of Huntington's Disease and Non-Alcoholic Steatohepatitis. | raptor8k_110112.htm |
| 2012-10-01 | 8-K | 2012-09-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | raptor8k092812.htm |
| 2012-09-12 | 8-K | 2012-09-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (b) On September 10, 2012, Kim R. Tsuchimoto ceased to serve as the Chief Financial Officer (principal financial officer and principal accounting officer) of Raptor Pharmaceutical Corp. (“Raptor”) and Raptor appointed Ms. Tsuchimoto as its Vice President, Finance. 8.01 On September 10, 2012, Raptor issued a press release announcing the appointment of Georgia Erbez as Chief Financial Officer of Raptor and the appointment of Kim R. Tsuchimoto as Vice President, Finance, transitioning from the position of Chief Financial Officer of Raptor. | d410177d8k.htm |
| 2012-08-20 | 8-K/A | 2012-08-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At the Company's 2012 Annual Meeting of Stockholders held on May 24, 2012, the Company's stockholders voted on, among other matters, a proposal on the frequency of future stockholder advisory votes on the compensation of the Company's named executive officers. | raptor8k081712.htm |
| 2012-07-31 | 8-K | 2012-07-30 | 8.01 Other Events | 8.01 On July 30, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that the European Patent Office has issued a key patent covering enteric-coated oral formulations of cysteamine bitartrate, including the Company's proprietary microbead formulation, RP103. | raptor8k073112.htm |
| 2012-07-12 | 8-K | 2012-07-11 | 8.01 Other Events | 8.01 On July 11, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release providing an update on its business and announcing its financial results for the third fiscal quarter ended May 31, 2012. | raptor8k071212.htm |
| 2012-06-25 | 8-K | 2012-06-25 | 8.01 Other Events | 8.01 On June 25, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that the dosing of a first patient in its Phase 2b juvenile clinical trial evaluating the safety and potential efficacy of RP103 as a potential treatment of non-alcoholic steatohepatitis, an advanced form of non-alcoholic fatty liver disease. | raptor8k062512.htm |
| 2012-06-19 | 8-K | 2012-06-18 | 8.01 Other Events | 8.01 On June 18, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that enrollment is complete in its Phase 2/3 clinical trial of Cysteamine Bitartrate Delayed-release Capsules (RP103) for the potential treatment of Huntington's Disease. | raptor8k0618.htm |
| 2012-06-14 | 8-K | 2012-06-13 | 8.01 Other Events | 8.01 On June 13, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for filing the Company's New Drug Application for its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules ("RP103"), for the potential treatment of nephropathic cystinosis. | raptor8k0613.htm |
| 2012-05-25 | 8-K | 2012-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2012 Annual Meeting of Stockholders (the "Annual Meeting") of Raptor Pharmaceutical Corp. (the "Company") was held on May 24, 2012. | raptor8k052412.htm |
| 2012-05-14 | 8-K | 2012-05-11 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On May 11, 2012, the Board of Directors (the “Board”) of Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), approved that certain amendment to the Bylaws of the Company, dated May 11, 2012 (the “Amendment”), to (i) reduce the quorum required for a meeting of stockholders from a majority to one-third of the outstanding shares of common stock issued and outstanding as of the record date and entitled to vote at such meeting, present either in person or by proxy, and (ii) update the name of the Company from TorreyPines Therapeutics, Inc. to Raptor Pharmaceutical Corp. Please see the discussion in Item 8.01 below. 8.01 On April 12, 2012, the Company adjourned the 2012 annual meeting of stockholders due to the lack of a requisite quorum. | raptor8k051412.htm |
| 2012-05-01 | 8-K | 2012-04-30 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On April 30, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to sell shares of the Company’s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $40,000,000, from time to time, through an “at the market” equity offering program under which Cowen will act as sales agent (the “Offering”). 8.01 On April 30, 2011, the Company issued a press release announcing the Offering. | raptor8k043012.htm |
| 2012-04-26 | 8-K | 2012-04-26 | 8.01 Other Events | 8.01 On April 26, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), announced that its 2012 annual meeting of stockholders scheduled for April 26, 2012, was adjourned due to the lack of requisite quorum. | raptor8k042612.htm |
| 2012-04-19 | 8-K | 2012-04-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 On April 16, 2012, Raptor Therapeutics Inc. (“Raptor Therapeutics”), a wholly-owned subsidiary of Raptor Pharmaceutical Corp. (the “Company”), entered into that certain Intellectual Property Platform Contribution Transaction License Agreement (the “Agreement”) with RPTP European Holdings, C.V. (“RPCV”), which is 99% owned by Raptor Therapeutics and 1% owned by Raptor European Products, LLC, a wholly-owned subsidiary of the Company. | raptor8k041912.htm |
| 2012-04-16 | 8-K | 2012-04-12 | 8.01 Other Events | 8.01 On April 12, 2012, the Company issued a press release announcing that the European Patent Office has issued a Notice of Allowance for a key patent covering the use of enteric-coated, delayed-release oral formulations of cysteamine bitartrate, including the Company’s proprietary microbead formulation, RP103, as well as other formulations of cystamine and cysteamine. | raptor8k041312.htm |
| 2012-04-12 | 8-K | 2012-04-12 | 8.01 Other Events | 8.01 On April 12, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), announced that its 2012 annual meeting of stockholders scheduled for April 12, 2012, was adjourned due to the lack of requisite quorum. | raptor8kmtg.htm |
| 2012-03-30 | 8-K | 2012-03-30 | 8.01 Other Events | 8.01 On March 30, 2012, the Company issued a press release announcing that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval to market its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules (RP103), for the treatment of nephropathic cystinosis. | raptor8k033012.htm |
| 2012-03-29 | 8-K | 2012-03-28 | 8.01 Other Events | 8.01 On March 28, 2012, the Company issued a press release announcing the appointment of Henk Doude van Troostwijk as General Manager of the Company’s European Commercial Operations, effective April 15, 2012. | raptor8k032812.htm |
| 2012-03-27 | 8-K | 2012-03-26 | 8.01 Other Events | 8.01 On March 26, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing that the European Medicines Agency has accepted the Company’s Marketing Authorization Application for its investigational drug candidate, RP103, formerly known as DR Cysteamine, for the treatment of nephropathic cystinosis. | raptor8k032612.htm |